Summary & Overview
HCPCS J9245: Melphalan Hydrochloride Injection, 50 mg
HCPCS Level II code J9245 designates a 50 mg vial of melphalan hydrochloride for injection, a cytotoxic chemotherapy agent used in oncology care. Nationally, accurate coding of chemotherapy drugs affects claim processing, allowed amounts, and patient cost-sharing across payers. This code is used where melphalan is administered parenterally in infusion centers, hospital outpatient departments, and physician offices.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing context and clinical setting for J9245, typical sites of service, common modifier usage (listed elsewhere), and which payers are commonly involved in reimbursement decisions. The publication outlines what to expect in benchmarks and payer coverage patterns, highlights relevant policy considerations that affect chemotherapy drug billing, and provides clinical context for melphalan use in oncology practice.
This summary is intended for national audiences seeking a clear reference for code identification, service setting, and payer landscape related to HCPCS Level II code J9245 for melphalan hydrochloride, 50 mg.
Billing Code Overview
HCPCS Level II code J9245 describes an injection of melphalan hydrochloride, not otherwise specified, 50 mg. This code represents a single-drug cytotoxic chemotherapy preparation intended for intravenous administration.
-
Service type: Chemotherapy drug administration (antineoplastic agent)
-
Typical site of service: Infusion center, hospital outpatient department, or physician office that provides parenteral chemotherapy services.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a hematologic malignancy such as multiple myeloma, ovarian cancer with intraperitoneal chemotherapy plan, or retinoblastoma where melphalan is indicated. The patient arrives to an oncology infusion center or hospital outpatient department for administration of J9245 (melphalan hydrochloride, 50 mg). Pre-treatment workflow includes verification of diagnosis and chemotherapy order, review of prior labs (complete blood count, renal and hepatic function), informed consent, and calculation of dose based on body surface area or protocol. Pharmacy prepares the drug under sterile technique and documents lot number and expiration; waste is recorded if partial vials are discarded. Nursing performs baseline assessment, places appropriate vascular access (peripheral IV, implanted port, or intra-arterial/intravitreal access depending on indication), initiates antiemetic prophylaxis as indicated, and administers the melphalan per protocol. Post-infusion monitoring includes vital signs, assessment for extravasation, and documentation of any immediate adverse effects. Typical sites of service are hospital outpatient infusion centers, physician offices with accredited infusion capabilities, ambulatory infusion centers, or operating rooms/interventional suites for intra-arterial or intravitreal administration. Billing uses J9245 per 50 mg vial; applicable modifiers reflect circumstances such as professional or facility billing, drug wasted, patient status, or unusual services. Documentation must include diagnosis linking to chemotherapy intent, ordered dose, lot number, administration route, site of service, and any applicable modifier rationale.
Coding Specifications
| Modifier | Description | When to Use |
|---|